MedicineWorld.Org
Your gateway to the world of medicine
Home
News
Cancer News
About Us
Cancer
Health Professionals
Patients and public
Contact Us
Disclaimer

Medicineworld.org: New Strategy For The Treatment Of CML

Back to cancer blog Blogs list Cancer blog  


Subscribe To Cancer Blog RSS Feed  RSS content feed What is RSS feed?

New Strategy For The Treatment Of CML

New Strategy For The Treatment Of CML
Virginia Commonwealth University Massey Cancer Center scientists have identified an approach to enhance the activity of a new anti-cancer agent that has already shown impressive efficacy in the therapy of chronic myelogenous leukemia.

Chronic myelogenous leukemia, or CML, is a cancer of the bone marrow caused by a specific genetic abnormality and is one of the more common forms of leukemia. Imatinib mesylate (Gleevec) is a highly effective anti-cancer agent that has revolutionized the course of treatment for patients with CML. It works by inhibiting the activity of a mutant protein, known as Bcr/ABl, which is responsible for this disease. However, despite initial success, patients eventually become resistant to imatinib mesylate.

As per Steven Grant, M.D., Massey's associate director for translational research and co-leader of the cancer center's cancer cell biology program, and senior author of the study, resistance to imatinib mesylate has prompted the development of newer generation inhibitors, such as a compound known as dasatinib, which are not only considerably more potent than imatinib mesylate, but also are active against cells expressing a number of of the mutations that make them resistant to the latter agent. Dasatinib also inhibits another important survival protein known as Src. However, Grant said that not all patients respond to dasatinib, and the risk remains that patients will develop resistance to this agent as well.

To address this problem, Grant and his colleagues examined the effects of combining dasatinib with PD184352, another clinically relevant small molecule inhibitor of a critical cellular survival pathway that inactivates an important survival protein known as ERK1/2 (extracellular-signal regulating kinase1/2). The article was pre-published as a First Edition Paper in Blood, the journal of the American Society of Hematology, which appeared online Jan. 11.

By blocking this pathway, PD184352 reduces the survival and proliferation in numerous tumor types, including leukemia cells. The team observed that combining extremely low concentrations of dasatinib with PD184352 resulted in a dramatic increase in apoptosis, or programmed cell death, in association with inactivation of multiple survival signaling pathways. Notably, enhanced lethality occurred in CML cells displaying various forms of imatinib mesylate resistance, said Grant.

"While the development of newer, more effective kinase inhibitors such as dasatinib for diseases such as CML is a clear priority, resistance of leukemia cells to these novel agents may also develop," said Grant.

"Addition of a second, targeted agent that potentiates the activity of dasatinib may reduce the leukemic burden further, and thereby reduce, or possibly even prevent the emergence of drug resistance. If validated, this concept could have significant implications for the therapy of CML and possibly other hematologic malignancies," said Grant.


Posted by: Janet    Source




Did you know?
Virginia Commonwealth University Massey Cancer Center scientists have identified an approach to enhance the activity of a new anti-cancer agent that has already shown impressive efficacy in the therapy of chronic myelogenous leukemia. Chronic myelogenous leukemia, or CML, is a cancer of the bone marrow caused by a specific genetic abnormality and is one of the more common forms of leukemia. Imatinib mesylate (Gleevec) is a highly effective anti-cancer agent that has revolutionized the course of treatment for patients with CML. It works by inhibiting the activity of a mutant protein, known as Bcr/ABl, which is responsible for this disease. However, despite initial success, patients eventually become resistant to imatinib mesylate.

Medicineworld.org: New Strategy For The Treatment Of CML

Main Page| Cancer blog| Cancer blogs list| Lung cancer blog| Colon cancer blog| Prostate cancer blog| Breast cancer blog| Diabetes watch blog| Heart watch blog| Allergy blog| Bladder cancer blog| Cervical cancer blog| Colon cancer news blog| Diabetes news blog| Esophageal cancer blog| Gastric cancer blog| Health news blog| Heart news blog| Infectious disease blog| Kidney watch blog| Lung disease blog| Lung cancer news blog| Mesothelioma blog| Neurology blog| Breast cancer news blog| OBGYN blog| Ophthalmology blog| Ovarian cancer blog| Cancer news blog| Pancreas cancer blog| Pediatrics blog| Prostate cancer news blog| Psychology blog| Research blog| Rheumatology blog| Society news blog| Uterine cancer blog| Weight watch blog|

Copyright statement
The contents of this web page are protected. Legal action may follow for reproduction of materials without permission.